Abstract: Provided are porous polymeric materials, methods of making same, and methods of using same. The porous polymeric materials include crosslinked calixarene moieties. The porous polymeric materials can be added to a sample and absorb/adsorb pollutants present in the sample. The absorbed/adsorbed pollutant can further be isolated from the porous polymeric material. The porous polymeric materials can be recycled.

Abstract: A functionally graded carbide body (400) can include a group 5 metal carbide substrate having a bulk composition region (410) that contains at least 70 wt % of a rhombohedral ?-phase carbide. A ?-phase-rich region (420) having a ?-phase-rich composition can be at a surface (430) of the substrate, and a phase composition gradient region (440) can transition from the ?-phase-rich composition region at the surface to the bulk composition region at a gradient depth (450) below the surface.

Abstract: This disclosure relates to methylsulfonamide derivatives and uses as imaging agents and other uses related to CXCR4 inhibition. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising compounds disclosed herein, derivatives, or pharmaceutically acceptable salts or prodrugs thereof. In certain embodiments, the compositions disclosed herein are used for imaging to study CXCR4 related conditions.

Abstract: Provided are porous polymeric materials, methods of making same, and methods of using same. The porous polymeric materials include crosslinked calixarene moieties. The porous polymeric materials can be added to a sample and absorb/adsorb pollutants present in the sample. The absorbed/adsorbed pollutant can further be isolated from the porous polymeric material. The porous polymeric materials can be recycled.

Abstract: A functionally graded carbide body (400) can include a group 5 metal carbide substrate having a bulk composition region (410) that contains at least 70 wt % of a rhombohedral ?-phase carbide. A ?-phase-rich region (420) having a ?-phase-rich composition can be at a surface (430) of the substrate, and a phase composition gradient region (440) can transition from the ?-phase-rich composition region at the surface to the bulk composition region at a gradient depth (450) below the surface.

Abstract: The present invention relates to a triazanonane derivative indicated by the chemical formula 1 below, or a pharmaceutically acceptable salt thereof, and a method for preparing same, and the triazanonane derivative according to the present invention forms a complex with a metal-fluoride and displays an effect of increasing the labeling efficiency up to 78-90% when labeling F-18, thus enabling use in various radioactive medicine labeling (In the chemical formula 1, R1, R2, A. E. X, n and m are as defined in the present description.

Abstract: The present invention relates to a triazanonane derivative indicated by the chemical formula 1 below, or a pharmaceutically acceptable salt thereof, and a method for preparing same, and the triazanonane derivative according to the present invention forms a complex with a metal-fluoride and displays an effect of increasing the labeling efficiency up to 78-90% when labeling F-18, thus enabling use in various radioactive medicine labeling (In the chemical formula 1, R1, R2, A. E. X, n and m are as defined in the present description.

Abstract: The present invention relates to novel amino acid derivatives containing heterocyclic chelating residues thereof; radioactive or nonradioactive metal complexes thereof; methods for preparation thereof; and apyrogenic and sterile preparative kits of the composition for targeting cancer cells. The compounds of the present invention can easily be taken up to cancer cells as they contain amino acid residues thereof; radioactive or nonradioactive metals can be labeled easily as they contain heterocyclic chelating residues thereof; cancer lesion can be imaged easily by targeting using the present invention.